Category Regulatory

Approval

Novocure’s Optune Lua Earns CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

Novocure’s Optune Lua® Earns CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer In a significant development for the treatment of advanced lung cancer, Novocure announced that its innovative device, Optune Lua®, has received the Conformité Européenne (CE) Mark,…

Read MoreNovocure’s Optune Lua Earns CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer
Verastem

Verastem Gets U.S. IND Clearance for KRAS G12D Inhibitor VS-7375, Paving Way for Phase 1/2a Trial in Solid Tumors

Verastem Gets U.S. IND Clearance for KRAS G12D Inhibitor VS-7375, Paving Way for Phase 1/2a Trial in Solid Tumors Verastem Oncology (Nasdaq: VSTM), a Boston-based biopharmaceutical company at the forefront of developing precision oncology therapies, has announced a significant milestone…

Read MoreVerastem Gets U.S. IND Clearance for KRAS G12D Inhibitor VS-7375, Paving Way for Phase 1/2a Trial in Solid Tumors
FDA

FDA Grants Breakthrough Status to BrainChild Bio’s CAR T Therapy for Pediatric Brain Tumors

FDA Grants Breakthrough Status to BrainChild Bio’s CAR T Therapy for Pediatric Brain Tumors BrainChild Bio, Inc., a clinical-stage biotechnology company at the forefront of neuro-oncology cell therapy innovation, has achieved a significant regulatory milestone with the announcement that its…

Read MoreFDA Grants Breakthrough Status to BrainChild Bio’s CAR T Therapy for Pediatric Brain Tumors
eGenesis

eGenesis and OrganOx Secure U.S. FDA IND Clearance for Acute-On-Chronic Liver Failure Treatment

eGenesis and OrganOx Secure U.S. FDA IND Clearance for Acute-On-Chronic Liver Failure Treatment eGenesis, a pioneering biotechnology company focused on developing human-compatible engineered organs, and OrganOx Ltd., a leading medical technology company specializing in organ preservation and support systems, today…

Read MoreeGenesis and OrganOx Secure U.S. FDA IND Clearance for Acute-On-Chronic Liver Failure Treatment
ImmunityBio

ImmunityBio Files Supplemental BLA for NMIBC and Expands ANKTIVA Access for Lymphopenia Treatment

ImmunityBio Files Supplemental BLA for NMIBC and Expands ANKTIVA Access for Lymphopenia Treatment ImmunityBio, Inc. (NASDAQ: IBRX), a leading company specializing in immunotherapy, has recently made significant strides in advancing its therapeutic offerings. The company announced the completion of multiple…

Read MoreImmunityBio Files Supplemental BLA for NMIBC and Expands ANKTIVA Access for Lymphopenia Treatment
Click Therapeutics

Click Therapeutics Secures FDA Approval for First-Ever Prescription Digital Migraine Therapy

Click Therapeutics Secures FDA Approval for First-Ever Prescription Digital Migraine Therapy In a significant milestone for digital health and the millions of people affected by migraine disorders, Click Therapeutics, Inc. has received marketing authorization from the U.S. Food and Drug…

Read MoreClick Therapeutics Secures FDA Approval for First-Ever Prescription Digital Migraine Therapy